Teligent (TLGTQ) 10-Q 14 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 01, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'IGI Laboratories, Inc.	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	43,758,415
Amendment Flag	'false	'
Entity Central Index Key	'0000352998	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Product sales, net	$3,950	$1,464	$11,124	$4,835
Research and development income	10	496	278	1,368
Licensing, royalty and other income	35	26	97	52
Total revenues	3,995	1,986	11,499	6,255
Cost of sales	2,684	1,222	7,932	4,271
Selling, general and administrative expenses	692	980	2,078	2,254
Product development and research expenses	661	620	2,123	1,735
Total costs and expenses	4,037	2,822	12,133	8,260
Operating loss	-42	-836	-634	-2,005
Interest expense and other, net	-53	-586	-121	-740
Net loss	($95)	($1,422)	($755)	($2,745)
Basic and diluted loss per share (in Dollars per share)	$0	($0.04)	($0.02)	($0.07)
Common Stock Equivalents Outstanding	'	'	'	'
Basic and diluted (in Shares)	43,395,980	39,508,217	43,179,898	39,510,540

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) (USD $)	Sep. 30, 2013	Dec. 31, 2012
ASSETS	'	'
Cash and cash equivalents	$1,402,000	$2,536,000	[1]
Accounts receivable, net	2,895,000	1,577,000	[1]
Inventories	2,523,000	1,773,000	[1]
Prepaid expenses and other receivables	232,000	253,000	[1]
Total current assets	7,052,000	6,139,000	[1]
Property, plant and equipment, net	2,634,000	2,691,000	[1]
Product acquisition costs, net	1,796,000	'	[1]
Restricted cash, long term	54,000	54,000	[1]
License fee, net	225,000	300,000	[1]
Debt issuance costs, net	77,000	100,000	[1]
Other	155,000	143,000	[1]
Total assets	11,993,000	9,427,000	[1]
LIABILITIES AND STOCKHOLDERS’ EQUITY	'	'
Accounts payable	1,561,000	1,091,000	[1]
Accrued expenses	1,079,000	820,000	[1]
Deferred income, current	179,000	48,000	[1]
Capital lease obligation, current	8,000	17,000	[1]
Total current liabilities	2,827,000	1,976,000	[1]
Note payable, bank	3,000,000	1,000,000	[1]
Deferred income, long term	6,000	20,000	[1]
Capital lease obligation, long term	'	4,000	[1]
Total liabilities	5,833,000	3,000,000	[1]
Commitments and contingencies	'	'	[1]
Common stock	457,000	446,000	[1]
Additional paid-in capital	48,386,000	47,409,000	[1]
Accumulated deficit	-44,200,000	-43,445,000	[1]
Total stockholders’ equity	6,160,000	6,427,000	[1]
Total liabilities and stockholders' equity	11,993,000	9,427,000	[1]
Series A Preferred Stock [Member]	'	'
LIABILITIES AND STOCKHOLDERS’ EQUITY	'	'
Convertible Preferred Stock	'	500,000	[1]
Series C Preferred Stock [Member]	'	'
LIABILITIES AND STOCKHOLDERS’ EQUITY	'	'
Convertible Preferred Stock	$1,517,000	$1,517,000	[1]
[1]	Derived from the audited December 31, 2012 financial statements

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Series A Preferred Stock [Member]	'	'
Convertible Preferred stock liquidation preference (in Dollars per share)	$0	$500,000	[1]
Series C Preferred Stock [Member]	'	'
Convertible Preferred stock liquidation preference (in Dollars per share)	$1,822,205	$1,764,240	[1]
[1]	Derived from the audited December 31, 2012 financial statements

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2013		Sep. 30, 2012
Cash flows from operating activities:	'		'
Net loss	($755,000)		($2,745,000)
Depreciation	280,000		264,000
Amortization of license fee	75,000		75,000
Stock-based compensation expense	169,000		320,000
Provision for write down of inventory	94,000		74,000
Amortization of debt issuance costs	23,000		642,000
Loss on abandonment of property	'		13,000
Accounts receivable	-1,318,000		22,000
Inventories	-844,000		-162,000
Prepaid expenses and other assets	9,000		210,000
Accounts payable and accrued expenses	729,000		96,000
Deferred income	117,000		-10,000
Net cash used in operating activities	-1,391,000		-1,201,000
Cash flows from investing activities:	'		'
Capital expenditures	-223,000		-323,000
Product acquisition costs	-1,826,000		'
Net cash used in investing activities	-2,049,000		-323,000
Cash flows from financing activities:	'		'
Proceeds from note payable, bank	2,000,000		1,000,000
Payment of debt issuance costs	'		-114,000
Payment on note payable, related party	'		-500,000
Principal payments on capital lease obligation	-13,000		-36,000
Proceeds from exercise of common stock options and warrants	372,000		35,000
Costs related to stock issuance	-53,000		'
Net cash provided by financing activities	2,306,000		385,000
Net decrease in cash and cash equivalents	-1,134,000		-1,139,000
Cash and cash equivalents at beginning of period	2,536,000	[1]	2,914,000
Cash and cash equivalents at end of period	1,402,000		1,775,000
Cash payments for interest	102,000		81,000
Cash payment for taxes	10,000		9,000
Common stock issued for Series A Convertible Preferred stock	500,000		'
Equipment purchases financed through capital leases	'		30,000
Forfeiture of restricted stock	'		1,000
Product Acquisition Costs [Member]	'		'
Cash flows from operating activities:	'		'
Amortization of product acquisition costs	$30,000		'
[1]	Derived from the audited December 31, 2012 financial statements

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) (USD $)	Stock Options other than restricted stock [Member]	Stock Options other than restricted stock [Member]	Restricted Stock [Member]	Restricted Stock [Member]	Preferred Stock [Member]	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
	Additional Paid-in Capital [Member]		Additional Paid-in Capital [Member]
Balance, December 31, 2012 (Audited) at Dec. 31, 2012	'	'	'	'	$500,000	$1,517,000	$446,000	$47,409,000	($43,445,000)	$6,427,000	[1]
Balance, December 31, 2012 (Audited) (in Shares) at Dec. 31, 2012	'	'	'	'	50	1,550	42,705,032	'	'	'
Stock based compensation expense	154,000	154,000	15,000	15,000	'	'	'	'	'	169,000
Stock warrants exercised	'	'	'	'	'	'	5,000	231,000	'	236,000
Stock warrants exercised (in Shares)	'	'	'	'	'	'	427,713	'	'	'
Stock options exercised	'	'	'	'	'	'	1,000	135,000	'	136,000
Stock options exercised (in Shares)	'	'	'	'	'	'	125,670	'	'	125,670
Costs related to stock issuance	'	'	'	'	'	'	'	-53,000	'	-53,000
Common stock issued for Series A Convertible Preferred stock	'	'	'	'	-500,000	'	5,000	495,000	'	'
Common stock issued for Series A Convertible Preferred stock (in Shares)	'	'	'	'	-50	'	500,000	'	'	'
Net loss	'	'	'	'	'	'	'	'	-755,000	-755,000
Balance, September 30, 2013 (Unaudited) at Sep. 30, 2013	'	'	'	'	'	$1,517,000	$457,000	$48,386,000	($44,200,000)	$6,160,000
Balance, September 30, 2013 (Unaudited) (in Shares) at Sep. 30, 2013	'	'	'	'	'	1,550	43,758,415	'	'	'
[1]	Derived from the audited December 31, 2012 financial statements

Note_1_Organization

Note 1 - Organization	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Nature of Operations [Text Block]	'
	1.     Organization
	IGI Laboratories, Inc. is a Delaware corporation incorporated in 1977. The Company’s office, laboratories and manufacturing facilities are located at 105 Lincoln Avenue, Buena, New Jersey. The Company is a developer, manufacturer, and marketer of topical formulations. The Company’s goal is to become a leader in the generic topical pharmaceutical market. In its own label, the Company sells generic topical pharmaceutical products that are bioequivalent to their brand name counterparts. The Company also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter (OTC), and cosmetic markets. The Company’s strategy is based on three initiatives:
		■	Manufacturing, developing, and marketing a portfolio of generic pharmaceutical products in its own label in topical dosage forms;
		■	Increasing the Company’s current contract manufacturing and development business; and
		■	Creating unique opportunities through the acquisition of additional intellectual property, and the expansion of the use of the Company’s existing intellectual property, including its licensed Novasome® technology.
	In December, 2012, the Company completed implementation of its commercial infrastructure and launched its first generic topical pharmaceutical products under the IGI label. As of November 14, 2013, the Company has filed thirteen Abbreviated New Drug Applications, or ANDAs, with the United States Food and Drug Administration, or FDA to date. As discussed in Note 10, on February 1, 2013, the Company acquired product rights to econozale nitrate cream 1%. The Company is now actively marketing four IGI label products in eight presentations of those products. The remainder of product sales are under contract manufacturing agreements. The Company performs all of its product development and manufacturing at its 25,000 square foot facility in Buena, New Jersey.

Note_2_Liquidity

Note 2 - Liquidity	9 Months Ended
	Sep. 30, 2013
Policy Text Block [Abstract]	'
Liquidity Disclosure [Policy Text Block]	'
	2.      Liquidity
	The Company’s principal sources of liquidity are cash and cash equivalents of approximately $1,402,000 at September 30, 2013 and cash from operations. The Company sustained net losses of $755,000 and $2,745,000 for the nine months ended September 30, 2013 and 2012, respectively, and had working capital of $4,225,000 at September 30, 2013.
	The Company’s business operations have been primarily funded over the past four years through funds available on its credit facility and private placements of its capital stock. The Company raised an aggregate of $2,000,000 through private placements of equity with accredited investors in 2012, $7,213,000 in 2010 and $5,304,000 in 2009 principally from private equity investors. The use of proceeds is intended for general working capital needs as well as the acquisition of econozale nitrate cream 1% which was purchased on February 1, 2013. The Company purchased a product and certain product rights which are expected to provide contribution to its gross profit in 2013 (See Note 10). In August 2012, the Company also entered into a $3,000,000 line of credit (See Note 8) and simultaneously drew down $1,000,000 under the credit facility. In February 2013, the Company drew down an additional $1,000,000 from the available credit facility and on August 2, 2013, the Company drew down an additional $1,000,000 from the available credit facility. As of September 30, 2013, the outstanding balance on the line of credit was $3,000,000. The Company may require additional funding and this funding will depend, in part, on the timing and structure of potential business arrangements. If necessary, the Company may continue to seek to raise additional capital through the sale of its equity. There may also be additional acquisition and growth opportunities that may require external financing. There can be no assurance that such financing will be available on terms acceptable to the Company, or at all. The Company also has the ability to defer certain product development and other programs, if necessary. The Company believes that its existing capital resources will be sufficient to support its current business plan and operations for at least the next twelve months.

Note_3_Summary_of_Significant_

Note 3 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	3.      Summary of Significant Accounting Policies
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include allowances for excess and obsolete inventories, allowances for doubtful accounts, provisions for income taxes and related deferred tax asset valuation allowance, stock based compensation, provisions for sales returns, chargebacks and other allowances, and accruals for environmental cleanup and remediation costs. Actual results could differ from those estimates.
	Loss Per Share
	Basic net loss per share of common stock is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock is computed using the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period. Due to the net loss for the three months ended September 30, 2013 and 2012 and the nine months ended September 30, 2013 and 2012, the effect of the Company’s potential dilutive common stock equivalents was anti-dilutive for each period; as a result, the basic and diluted weighted average number of common shares outstanding and net loss per common share are the same. Potentially dilutive common stock equivalents include options and warrants to purchase the Company’s common stock and the conversion of preferred stock, which were excluded from the net loss per share calculations due to their anti-dilutive effect amounted to 5,602,089 for 2013 and 5,913,604 for 2012.
	Revenue Recognition
	The Company considers revenue realized or realizable and earned when it has persuasive evidence of an arrangement, delivery has occurred or contractual services rendered, the sales price is fixed or determinable, and collection is reasonably assured in conformity with ASC 605, Revenue Recognition.
	The Company derives its revenues from three basic types of transactions: sales of its own generic pharmaceutical topical products, sales of manufactured product for its customers, and research and product development services performed for third parties.  Due to differences in the substance of these transaction types, the transactions require, and the Company utilizes, different revenue recognition policies for each.
	Product Sales: Product Sales includes IGI Product Sales and Contract Manufacturing Sales.
	IGI Product Sales: The Company records revenue from IGI product sales when title and risk of ownership have been transferred to the customer, which is typically upon delivery of products to the customer.
	Revenue and Provision for Sales Returns and Allowances
	As customary in the pharmaceutical industry, the Company’s gross product sales from IGI label products are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes revenue from the sale of products, an estimate of sales returns and allowances (“SRA”) is recorded, which reduces product sales. Accounts receivable and/or accrued expenses are also reduced and/or increased by the SRA amount. These adjustments include estimates for chargebacks, rebates, cash discounts and returns and other allowances. Currently these provisions are based on industry standards and current contract sales terms with direct and indirect customers. Over time, these provisions will be adjusted as estimates will be based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and current contract sales terms with direct and indirect customers. The estimation process used to determine our SRA provision has been applied on a consistent basis and no material adjustments have been necessary to increase or decrease our reserves for SRA as a result of a significant change in underlying estimates. The Company will use a variety of methods to assess the adequacy of our SRA reserves to ensure that our financial statements are fairly stated. These will include periodic reviews of customer inventory data, customer contract programs and product pricing trends to analyze and validate the SRA reserves.
	The provision for chargebacks is our most significant sales allowance. A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid to the Company by our wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The Company’s chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at contract prices. The Company will validate the chargeback accrual quarterly through a review of the inventory reports obtained from our largest wholesale customers. This customer inventory information is used to verify the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent 90% - 95% of the Company’s chargeback payments. The Company continually monitors current pricing trends and wholesaler inventory levels to ensure the liability for future chargebacks is fairly stated.
	Net revenues and accounts receivable balances in the Company’s consolidated financial statements are presented net of SRA estimates. Certain SRA balances are included in accounts payable and accrued expenses.
	Gross-To-Net Sales Deductions
		Three months ended September 30,					Nine months ended September 30,
		2013			2012		2013			2012
	Gross IGI product sales:	$	3,038		$	-	$	7,417		$	-
	Reduction to gross product sales:
	Chargebacks and billbacks		(1,395	)		-		(2,618	)		-
	Sales discounts and other allowances		(254	)		-		(619	)		-
	Total reduction to gross product sales	$	(1,649	)		-	$	(3,237	)		-
	Net IGI product sales	$	1,389			-	$	4,180			-
	Accounts receivable are presented net of SRA balances of $0.5 million and $0 at September 30, 2013 and 2012, respectively. Accounts payable and accrued expenses include $0.3 million and $0 at September 30, 2013 and 2012, respectively, for certain fees related to services provided by the wholesalers. Wholesale fees of $0.1 million and $0 for the three month periods ended September 30, 2013 and 2012, respectively, were included in cost of goods sold. Wholesale fees of $0.4 million and $0 for the nine month periods ended September 30 for 2013 and 2012, respectively, were included in cost of goods sold. In addition, in connection with three of the four products the Company currently manufactures, markets and distributes in its own label, in accordance with an agreement entered into in December of 2011, the Company is required to pay a royalty calculated based on net sales to one of its pharmaceutical partners. In accordance with the agreement, net sales excludes fees related to services provided by the wholesalers. Accounts payable and accrued expenses include $0.5 million and $0 at September 30, 2013 and 2012, respectively, related to these royalties. Royalty expense of $0.5 million and $0 was included in cost of goods sold for the three months ended September 30, 2013 and 2012, respectively. Royalty expense of $1.5 million and $0 was included in cost of goods sold for the nine months ended September 30 for 2013, and 2012 respectively. The Company includes significant estimates to arrive at net product sales arising from wholesaler chargebacks, Medicaid and Medicare rebates, allowances and other pricing and promotional programs.
	Contract Manufacturing Sales: The Company recognizes revenue when title transfers to its customers, which is generally upon shipment of products. These shipments are made in accordance with sales commitments and related sales orders entered into with customers either verbally or in written form. The revenues associated with these transactions, net of appropriate cash discounts, product returns and sales reserves, are recorded upon shipment of the products.
	Research and Development Income:  The Company establishes agreed upon product development agreements with its customers to perform product development services. Product development revenues are recognized in accordance with the product development agreement upon the completion of the phases of development and when the Company has no future performance obligations relating to that phase of development. Revenue recognition requires the Company to assess progress against contracted obligations to assure completion of each stage. These payments are generally non-refundable and are reported as deferred until they are recognizable as revenue. If no such arrangement exists, product development fees are recognized ratably over the entire period during which the services are performed.
	In making such assessments, judgments are required to evaluate contingencies such as potential variances in schedule and the costs, the impact of change orders, liability claims, contract disputes and achievement of contractual performance standards. Changes in total estimated contract cost and losses, if any, are recognized in the period they are determined. Billings on research and development contracts are typically based upon terms agreed upon by the Company and customer and are stated in the contracts themselves and do not always align with the revenues recognized by the Company.
	Major Customers
	Major customers of the Company are defined as having revenue greater than 10% of total gross revenue. For the three months ended September 30, 2013, three of the Company’s customers accounted for 49% of the Company’s revenue. For the three months ended September 30, 2012, four of the Company’s customers accounted for 80% of the Company’s revenue. One of these customers is the same for both periods. For the nine months ended September 30, 2013 and 2012, four of the Company’s customers accounted for 55% and three of the Company’s customers accounted for 65% of the Company’s revenue, respectively. Two of these customers are the same for both periods. Accounts receivable related to the Company’s major customers comprised 54% of all accounts receivable as of September 30, 2013. The loss of one or more of these customers could have a significant impact on our revenues and harm our business and results of operations.
	Recent Accounting Pronouncements
	In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When A Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”), which provides guidance on the presentation of unrecognized tax benefits when net operating loss carryforwards, similar tax losses, or tax credit carryforwards exist. The amendments in this update are effective for fiscal years (and interim periods within those years) beginning after December 15, 2013. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The Company does not expect ASU 2013-11 to have a material effect on its financial condition, results of operation or cash flows. This update will be effective for the Company for the year beginning January 1, 2014.

Note_4_Inventories

Note 4 - Inventories	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	4.      Inventories
	Inventories are valued at the lower of cost, using the first-in, first-out (“FIFO”) method, or market. Inventories at September 30, 2013 and December 31, 2012 consist of:
			30-Sep-13		31-Dec-12
			(Unaudited)		(Audited)
			(amounts in thousands)
	Raw materials	$	2,081	$	1,673
	Work in progress		162		26
	Finished goods		280		74
	Total	$	2,523	$	1,773

Note_5_StockBased_Compensation

Note 5 - Stock-Based Compensation	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	5.      Stock-Based Compensation
	Under the 1998 Directors Stock Plan, as amended, 600,000 shares of the Company’s common stock are authorized under the plan and reserved for issuance to non-employee directors, in lieu of payment of directors’ fees in cash. In November 2009, the Company’s Board of Directors approved the elimination of payment of directors’ fees in stock under this plan beginning in the fourth quarter of 2009.
	The 1999 Director Stock Option Plan, as amended (the “Director Plan”), provides for the grant of stock options to non-employee directors of the Company at an exercise price equal to the fair market value per share on the date of the grant. An aggregate of 1,975,000 shares have been approved and authorized for issuance pursuant to this plan. A total of 2,179,798 options have been granted to non-employee directors through September 30, 2013 and 727,782 of those have been forfeited through September 30, 2013 and returned to the option pool. The options granted under the Director Plan vest in full one year after their respective grant dates and have a maximum term of ten years.
	The 1999 Stock Incentive Plan, as amended (the “1999 Plan”), replaced all previously authorized employee stock option plans, and no additional options may be granted under those plans. Under the 1999 Plan, options or stock awards may be granted to all of the Company's employees, officers, directors, consultants and advisors to purchase a maximum of 3,200,000 shares of common stock. However, pursuant to the terms of the 1999 Plan, no awards may be granted after March 16, 2009. A total of 2,892,500 options, having a maximum term of ten years, has been granted at 100% of the fair market value of the Company's common stock at the time of grant. Options outstanding under the 1999 Plan are generally exercisable in cumulative increments over four years commencing one year from the date of grant.
	On June 26, 2009, the Board of Directors adopted, and the Company’s stockholders subsequently approved by partial written consent, the IGI Laboratories, Inc. 2009 Equity Incentive Plan (the “2009 Plan”). The 2009 Plan allows the Company to continue to grant options and restricted stock, as under the 1999 Plan, but also authorizes the Board of Directors to grant a broad range of other equity-based awards, including stock appreciation rights, restricted stock units and performance awards. The 2009 Plan has been created, pursuant to and consistent with the Company’s current compensation philosophy, to assist the Company in attracting, retaining and rewarding designated employees, directors, consultants and other service providers of the Company and its subsidiaries and affiliates, in a manner that will be cost efficient to the Company from both an economic and financial accounting perspective. On April 12, 2010, the Board of Directors adopted, and the Company’s stockholders subsequently approved, an amendment and restatement of the 2009 Plan to increase the number of shares of common stock available for grant under such plan by adding 2,000,000 shares of common stock. The 2009 Plan, as amended on May 19, 2010, authorizes up to 4,000,000 shares of the Company’s common stock for issuance pursuant to the terms of the 2009 Plan. The maximum number of shares that may be subject to awards made to any individual in any single calendar year under the 2009 Plan is 1,000,000 shares. As of September 30, 2013, options to purchase 1,882,666 shares of common stock were outstanding under the 2009 Plan and 1,148,748 shares of restricted stock had been granted under the 2009 Plan, 230,420 of those have been forfeited through September 30, 2013 and returned to the pool.
	In aggregate, there are 2,606,666 options outstanding under the 1999 Plan, the Director Plan and the 2009 Plan, collectively, as of September 30, 2013.
	Stock Options
	The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities and risk-free interest rates are based upon the expected life of the grant. The interest rates used are the U.S. Treasury yield curve in effect at the time of the grant.
		For the nine months ended
		30-Sep-13
	Expected volatility	36.90%		-		40.40%
	Expected term (in years)	3.2		-		3.3
	Risk-free rate				0.49%
	Expected dividends				0%
	A summary of option activity under the 1999 Plan, the Director Plan and the 2009 Plan as of September 30, 2013 and changes during the period are presented below:
			Number of				Weighted
			Options				Average
							Exercise Price
	Outstanding as of January 1, 2013			2,606,500			$	1.1
	Issued			205,500			$	1.2
	Exercised			(125,670	)		$	1.08
	Forfeited			(79,664	)		$	1.31
	Expired			-				-
	Outstanding as of September 30, 2013			2,606,666			$	1.1
	Exercisable as of September 30, 2013			1,356,831			$	1.14
	Based upon application of the Black-Scholes option-pricing formula described above, the weighted-average grant-date fair value of options granted during the nine months ended September 30, 2013 was $0.33.
	The following table summarizes information regarding options outstanding and exercisable at September 30, 2013:
	Range of Exercise Prices					Stock Options		Weighted	Weighted
						Outstanding		Average	Average
								Exercise	Remaining
								Price	Contractual Life
	$0.55			$1.00		218,000		$0.76	5.08
	$1.01			$1.50		2,218,666		$1.09	8.17
	$1.51			$1.95		170,000		$1.68	7.54
	Total					2,606,666		$1.10	7.87
	Range of Exercise Prices
					Stock			Weighted
					Options			Average
					Exercisable			Exercise Price
	$0.55		$1.00		214,000			0.75
	$1.01		$1.50		992,831			1.14
	$1.51		$1.95		150,000			1.67
	Total				1,356,831			1.14
	As of September 30, 2013, the intrinsic value of the options outstanding is $1,873,180 and the intrinsic value of the options exercisable is $929,055. The total intrinsic value of the options exercised during the nine months ended September 30, 2013 was $92,976. As of September 30, 2013, there was approximately $312,000 of total unrecognized compensation cost that will be recognized through September 2016 related to non-vested share-based compensation arrangements granted under the equity plans.
	Restricted Stock
	The Company periodically grants restricted stock awards to certain officers and other employees that typically vest one to three years from their grant date. The Company recognized $4,900 and $104,200 of compensation expense during the three months ended September 30, 2013 and 2012, respectively, related to restricted stock awards.  Stock compensation expense is recognized over the vesting period of the restricted stock.  At September 30, 2013, the Company had approximately $6,500 of total unrecognized compensation cost related to non-vested restricted stock, all of which will be recognized from July 2013 through January 2014.
			Number of				Weighted Average
			Restricted Stock				Exercise Price
	Non-vested balance at January 1, 2013			29,334			$	1
	Changes during the period:
	Shares granted			-				-
	Shares vested			-				-
	Shares forfeited			-				-
	Non-vested balance at September 30, 2013			29,334			$	1

Note_6_Income_Taxes

Note 6 - Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	6.      Income Taxes
	As a result of the Company’s history of continuing tax losses, the Company does not have a current tax provision and has recorded a full valuation allowance against its net deferred tax asset. The Company has not recorded a liability for unrecognized tax benefits at September 30, 2013 and no significant changes are expected in the next twelve months. The tax years 2009-2012 remain open to examination by the major taxing jurisdictions to which the Company is subject.
	There was no accrued interest related to unrecognized tax benefits at September 30, 2013.
	The Company’s ability to use net operating loss carry forwards may be subject to substantial limitation in future periods under certain provisions of Section 382 of the Internal Revenue Code, which limit the utilization of net operating losses upon a more than 50% change in ownership of the Company’s stock that is held by 5% or greater stockholders. The Company examined the application of Section 382 with respect to an ownership change that took place during 2009 and 2010, as well as the possibility of such limitation having any material effect on the application of net operating loss carry forwards in the immediate future. The Company believes that it is likely that a change in ownership took place and that the net operating loss carry forwards will be limited.

Note_7_License_Fee

Note 7 - License Fee	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block Supplement [Abstract]	'
Commitments Disclosure [Text Block]	'
	7.      License Fee
	On December 12, 2005, the Company extended its license agreement for an additional ten years with Novavax, Inc. for $1,000,000. This extension entitles the Company to exclusively use of the Novasome® lipid vesicle encapsulation and certain other technologies in the fields of (i) animal pharmaceuticals, biologicals and other animal health products; (ii) foods, food applications, nutrients and flavorings; (iii) cosmetics, consumer products and dermatological over-the-counter and prescription products (excluding certain topically delivered hormones); (iv) fragrances; and (v) chemicals, including herbicides, insecticides, pesticides, paints and coatings, photographic chemicals and other specialty chemicals, and the processes for making the same through 2015. This payment is being amortized ratably over the ten-year period. The Company recorded amortization expense of $25,000 related to this agreement for each of the three month periods ended September 30, 2013 and 2012 and amortization expense of $75,000 related to this agreement for each of the nine months ended September 30, 2013 and 2012.

Note_8_Note_Payable_Bank

Note 8 - Note Payable - Bank	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	8.      Note Payable - Bank
	On August 31, 2012, IGI Laboratories, Inc. and its subsidiaries, Igen, Inc. and IGI Labs, Inc., entered into a Loan and Security Agreement (the “Loan and Security Agreement”) with Square 1 Bank (the “Lender”) pursuant to which the Lender agreed to extend credit facilities to the Company (the “Financing”). The Company drew down $1,000,000 in principal amount on August 31, 2012, $1,000,000 in principal amount on February 5, 2013 and $1,000,000 in principal amount on August 2, 2013.
	To secure payment of the amounts financed under the Loan and Security Agreement, the Company has granted to the Lender a continuing security interest in and against, generally, all of its tangible and intangible assets, except intellectual property.
	Under the Loan and Security Agreement, the Company can request revolving loan advances under (a) the Formula Revolving Line and (b) the Non-Formula Revolving Line, and term loan advances under the term loans. The aggregate total borrowings under the facilities cannot exceed the total borrowing limit of $3,000,000 at any one time outstanding. Formula Revolving Line advances shall bear interest, on the outstanding balance thereof, at a variable rate equal to the greater of (A) 1.9% above the prime rate then in effect, and (B) 5.65%. Non-Formula Revolving Line advances shall bear interest, on the outstanding balance thereof, at a variable rate equal to the greater of (A) 2.15% above the prime rate then in effect, and (B) 5.9%. Term loan advances shall bear interest, on the outstanding balance thereof, at a variable rate equal to the greater of (A) 2.4% above the prime rate then in effect, and (B) the rate in effect at December 31, 2012, which was 6.15%.
	The term of the Formula Revolving Line and the Non-Formula Revolving Line is one year from the date of the Loan and Security Agreement and can be extended by mutual agreement of the parties. The term of the term loans is 42 months from the date of the Loan and Security Agreement, but term loan advances are available to the Company only until February 28, 2014.
	In accordance with the Loan and Security Agreement, the Company must maintain a liquidity ratio of at least 1.25 to 1.00 (the “LQR Threshold”), provided that the LQR Threshold shall be reduced to 1.00 to 1.00 so long as the Company has achieved minimum Revenue, measured monthly on a trailing three month basis, of at least the amounts listed in the document for the corresponding reporting periods. To further clarify, if at any time the Company is not in compliance with the minimum revenue amounts set forth below, the LQR Threshold shall be increased to 1.25 to 1.00. “Liquidity” means the sum of: (i) unrestricted cash in bank plus (ii) the Borrowing Base (the amount drawn to date). In accordance with the Loan and Security Agreement, liquidity ratio means the ratio of Liquidity to all Indebtedness to the Lender (but excluding any Indebtedness to the Lender which is secured by cash held in a segregated deposit account at the Lender). As of September 30, 2013, the Company was in compliance with the LQR Threshold required under the Loan and Security Agreement.
	In connection with the Financing, the Company paid in full its existing credit facility with Amzak Capital Management, LLC (see Note 9 below) and executed a Release and Termination Note and Credit Agreement with Amzak Capital Management, LLC to release the Company from any future obligations under the Credit Agreement executed on December 21, 2010 (the “Amzak Credit Facility ”).
	On July 26, 2013, the Company entered into an Amendment to the Loan and Security Agreement (the “Amendment”). In accordance with the Amendment, notwithstanding the existing LQR Thresholds, for so long as the Company is in compliance with the minimum revenue requirements established in this Amendment, the Company shall be permitted to maintain a liquidity ratio of not less than .90 to 1.00 for a continuous 60 day period every 12 months. In connection with the lower liquidity ratio, in accordance with the Amendment, under the Formula Revolving Line advances shall bear interest, on the outstanding balance thereof, at a variable rate equal to the greater of (A) 4.9% above the prime rate then in effect, and (B) 8.65%. Non-Formula Revolving Line advances shall bear interest, on the outstanding balance thereof, at a variable rate equal to the greater of (A) 5.15% above the prime rate then in effect, and (B) 8.9%, until such time that the lower liquidity ratio is no longer in place. If the Company remains in compliance through the end of December of 2013, the aggregate borrowing amount will be increased from $3,000,000 to $5,000,000.

Note_9_Stock_Warrants

Note 9 - Stock Warrants	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	9.     Stock Warrants
	Stock Warrants activity for the nine months ended September 30, 2013 and 2012 consisted of:
			2013					2012
		Warrants			Weighted		Warrants		Weighted
					Average				Average
					Exercise Price				Exercise Price
	Beginning balance		782,259		$	0.85		1,235,877	$	0.35
	Stock warrants granted		-			-		-		-
	Stock warrants expired		-			-		-		-
	Stock warrants exercised		(427,713	)		0.55		-		-
	Ending balance		354,546		$	1.21		1,235,877	$	0.35
	In connection with the private placement of the Company’s Common Stock on December 8, 2010, the Company granted common stock warrants to purchase 338,182 and 16,364 shares, respectively, to each of its two placement agents for $1.21 per share which expire on December 8, 2015. In connection with the private placement of the Company’s common stock in 2012, the Company granted common stock warrants to purchase 387,201 shares for $0.01 per share, which expire December 2022.
	In addition, the Company executed as of December 31, 2012 a settlement agreement with Amzak Capital Management, LLC (“Amzak”) in connection with a common stock purchase warrant issued to Amzak on December 21, 2012 under which the Company issued a ten-year warrant to purchase up to 427,713 shares of the Company’s common stock, with an exercise price of $0.55 per share. The warrants were exercised in full on February 8, 2013. The amount of the fair value of the warrant issued was $209,000, and included as interest expense in 2012, as it related to the credit agreement which was terminated in August of 2012.

Note_10_Asset_Purchase_Agreeme

Note 10 - Asset Purchase Agreement	9 Months Ended
	Sep. 30, 2013
Asset Purchase Agreement Disclosure [Abstract]	'
Asset Purchase Agreement Disclosure [Text Block]	'
	10.  Asset Purchase Agreement
	On February 1, 2013, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Prasco, LLC, an Ohio limited liability company (“Prasco”), pursuant to which the Company purchased from Prasco assets associated with econazole nitrate cream 1% (the “Product”), which is available in 15g, 30g, and 85g tubes has United States Food and Drug Administration approved indications for the treatment of tinea pedis, tinea cruris, and tinea corporis as well as the treatment of cutaneous candidiasis and tinea versicolor.
	In consideration for the purchase of the assets pursuant to the Purchase Agreement, the Company paid Prasco $1.4 million in cash and paid an additional aggregate of $400,000 upon the occurrence of the milestone events (the “Milestone Payment”). The Milestone Payment is secured by a first-priority security interest in the acquired assets under the Purchase Agreement. The transaction is accounted for as a purchase of the product and product rights, and as such the initial payment and related costs to acquire the asset are included as part of product acquisition costs totaling $1.4 million.  The Company capitalized the remaining milestone payment and related acquisition costs and amortized the costs over fifteen years, the useful life of the acquired product and product rights.
	Under and subject to the terms and conditions of the Purchase Agreement, Prasco continued to distribute the Product during a six-month period following the closing of the Purchase Agreement, and the Company completed the technical transfer of the Product and begun manufacturing the Product under its own label during the third quarter of 2013. The Company’s product sales in the third quarter included sales of the product.
	In addition, the Purchase Agreement contains certain non-compete restrictions preventing Prasco from selling the Product in United States for a period of seven years.
	On October 23, 2013, the Company announced that it had received formal approval from the U.S. Food and Drug Administration (FDA) for the CBE-30 supplemental filing to approve the site transfer of the econazole nitrate cream 1%, to the Company’s manufacturing facility in Buena, NJ.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include allowances for excess and obsolete inventories, allowances for doubtful accounts, provisions for income taxes and related deferred tax asset valuation allowance, stock based compensation, provisions for sales returns, chargebacks and other allowances, and accruals for environmental cleanup and remediation costs. Actual results could differ from those estimates.
Earnings Per Share, Policy [Policy Text Block]	'
	Loss Per Share
	Basic net loss per share of common stock is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock is computed using the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period. Due to the net loss for the three months ended September 30, 2013 and 2012 and the nine months ended September 30, 2013 and 2012, the effect of the Company’s potential dilutive common stock equivalents was anti-dilutive for each period; as a result, the basic and diluted weighted average number of common shares outstanding and net loss per common share are the same. Potentially dilutive common stock equivalents include options and warrants to purchase the Company’s common stock and the conversion of preferred stock, which were excluded from the net loss per share calculations due to their anti-dilutive effect amounted to 5,602,089 for 2013 and 5,913,604 for 2012.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	The Company considers revenue realized or realizable and earned when it has persuasive evidence of an arrangement, delivery has occurred or contractual services rendered, the sales price is fixed or determinable, and collection is reasonably assured in conformity with ASC 605, Revenue Recognition.
	The Company derives its revenues from three basic types of transactions: sales of its own generic pharmaceutical topical products, sales of manufactured product for its customers, and research and product development services performed for third parties.  Due to differences in the substance of these transaction types, the transactions require, and the Company utilizes, different revenue recognition policies for each.
	Product Sales: Product Sales includes IGI Product Sales and Contract Manufacturing Sales.
	IGI Product Sales: The Company records revenue from IGI product sales when title and risk of ownership have been transferred to the customer, which is typically upon delivery of products to the customer.
	Revenue and Provision for Sales Returns and Allowances
	As customary in the pharmaceutical industry, the Company’s gross product sales from IGI label products are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes revenue from the sale of products, an estimate of sales returns and allowances (“SRA”) is recorded, which reduces product sales. Accounts receivable and/or accrued expenses are also reduced and/or increased by the SRA amount. These adjustments include estimates for chargebacks, rebates, cash discounts and returns and other allowances. Currently these provisions are based on industry standards and current contract sales terms with direct and indirect customers. Over time, these provisions will be adjusted as estimates will be based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and current contract sales terms with direct and indirect customers. The estimation process used to determine our SRA provision has been applied on a consistent basis and no material adjustments have been necessary to increase or decrease our reserves for SRA as a result of a significant change in underlying estimates. The Company will use a variety of methods to assess the adequacy of our SRA reserves to ensure that our financial statements are fairly stated. These will include periodic reviews of customer inventory data, customer contract programs and product pricing trends to analyze and validate the SRA reserves.
	The provision for chargebacks is our most significant sales allowance. A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid to the Company by our wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The Company’s chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at contract prices. The Company will validate the chargeback accrual quarterly through a review of the inventory reports obtained from our largest wholesale customers. This customer inventory information is used to verify the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent 90% - 95% of the Company’s chargeback payments. The Company continually monitors current pricing trends and wholesaler inventory levels to ensure the liability for future chargebacks is fairly stated.
	Net revenues and accounts receivable balances in the Company’s consolidated financial statements are presented net of SRA estimates. Certain SRA balances are included in accounts payable and accrued expenses.
	Gross-To-Net Sales Deductions
		Three months ended September 30,					Nine months ended September 30,
		2013			2012		2013			2012
	Gross IGI product sales:	$	3,038		$	-	$	7,417		$	-
	Reduction to gross product sales:
	Chargebacks and billbacks		(1,395	)		-		(2,618	)		-
	Sales discounts and other allowances		(254	)		-		(619	)		-
	Total reduction to gross product sales	$	(1,649	)		-	$	(3,237	)		-
	Net IGI product sales	$	1,389			-	$	4,180			-
	Accounts receivable are presented net of SRA balances of $0.5 million and $0 at September 30, 2013 and 2012, respectively. Accounts payable and accrued expenses include $0.3 million and $0 at September 30, 2013 and 2012, respectively, for certain fees related to services provided by the wholesalers. Wholesale fees of $0.1 million and $0 for the three month periods ended September 30, 2013 and 2012, respectively, were included in cost of goods sold. Wholesale fees of $0.4 million and $0 for the nine month periods ended September 30 for 2013 and 2012, respectively, were included in cost of goods sold. In addition, in connection with three of the four products the Company currently manufactures, markets and distributes in its own label, in accordance with an agreement entered into in December of 2011, the Company is required to pay a royalty calculated based on net sales to one of its pharmaceutical partners. In accordance with the agreement, net sales excludes fees related to services provided by the wholesalers. Accounts payable and accrued expenses include $0.5 million and $0 at September 30, 2013 and 2012, respectively, related to these royalties. Royalty expense of $0.5 million and $0 was included in cost of goods sold for the three months ended September 30, 2013 and 2012, respectively. Royalty expense of $1.5 million and $0 was included in cost of goods sold for the nine months ended September 30 for 2013, and 2012 respectively. The Company includes significant estimates to arrive at net product sales arising from wholesaler chargebacks, Medicaid and Medicare rebates, allowances and other pricing and promotional programs.
	Contract Manufacturing Sales: The Company recognizes revenue when title transfers to its customers, which is generally upon shipment of products. These shipments are made in accordance with sales commitments and related sales orders entered into with customers either verbally or in written form. The revenues associated with these transactions, net of appropriate cash discounts, product returns and sales reserves, are recorded upon shipment of the products.
	Research and Development Income:  The Company establishes agreed upon product development agreements with its customers to perform product development services. Product development revenues are recognized in accordance with the product development agreement upon the completion of the phases of development and when the Company has no future performance obligations relating to that phase of development. Revenue recognition requires the Company to assess progress against contracted obligations to assure completion of each stage. These payments are generally non-refundable and are reported as deferred until they are recognizable as revenue. If no such arrangement exists, product development fees are recognized ratably over the entire period during which the services are performed.
	In making such assessments, judgments are required to evaluate contingencies such as potential variances in schedule and the costs, the impact of change orders, liability claims, contract disputes and achievement of contractual performance standards. Changes in total estimated contract cost and losses, if any, are recognized in the period they are determined. Billings on research and development contracts are typically based upon terms agreed upon by the Company and customer and are stated in the contracts themselves and do not always align with the revenues recognized by the Company.
Major Customers, Policy [Policy Text Block]	'
	Major Customers
	Major customers of the Company are defined as having revenue greater than 10% of total gross revenue. For the three months ended September 30, 2013, three of the Company’s customers accounted for 49% of the Company’s revenue. For the three months ended September 30, 2012, four of the Company’s customers accounted for 80% of the Company’s revenue. One of these customers is the same for both periods. For the nine months ended September 30, 2013 and 2012, four of the Company’s customers accounted for 55% and three of the Company’s customers accounted for 65% of the Company’s revenue, respectively. Two of these customers are the same for both periods. Accounts receivable related to the Company’s major customers comprised 54% of all accounts receivable as of September 30, 2013. The loss of one or more of these customers could have a significant impact on our revenues and harm our business and results of operations.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements
	In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When A Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”), which provides guidance on the presentation of unrecognized tax benefits when net operating loss carryforwards, similar tax losses, or tax credit carryforwards exist. The amendments in this update are effective for fiscal years (and interim periods within those years) beginning after December 15, 2013. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The Company does not expect ASU 2013-11 to have a material effect on its financial condition, results of operation or cash flows. This update will be effective for the Company for the year beginning January 1, 2014.

Note_3_Summary_of_Significant_1

Note 3 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	'
	Gross-To-Net Sales Deductions
		Three months ended September 30,					Nine months ended September 30,
		2013			2012		2013			2012
	Gross IGI product sales:	$	3,038		$	-	$	7,417		$	-
	Reduction to gross product sales:
	Chargebacks and billbacks		(1,395	)		-		(2,618	)		-
	Sales discounts and other allowances		(254	)		-		(619	)		-
	Total reduction to gross product sales	$	(1,649	)		-	$	(3,237	)		-
	Net IGI product sales	$	1,389			-	$	4,180			-

Note_4_Inventories_Tables

Note 4 - Inventories (Tables)	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
			30-Sep-13		31-Dec-12
			(Unaudited)		(Audited)
			(amounts in thousands)
	Raw materials	$	2,081	$	1,673
	Work in progress		162		26
	Finished goods		280		74
	Total	$	2,523	$	1,773

Note_5_StockBased_Compensation1

Note 5 - Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
		For the nine months ended
		30-Sep-13
	Expected volatility	36.90%		-		40.40%
	Expected term (in years)	3.2		-		3.3
	Risk-free rate				0.49%
	Expected dividends				0%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
			Number of				Weighted
			Options				Average
							Exercise Price
	Outstanding as of January 1, 2013			2,606,500			$	1.1
	Issued			205,500			$	1.2
	Exercised			(125,670	)		$	1.08
	Forfeited			(79,664	)		$	1.31
	Expired			-				-
	Outstanding as of September 30, 2013			2,606,666			$	1.1
	Exercisable as of September 30, 2013			1,356,831			$	1.14
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
	Range of Exercise Prices					Stock Options		Weighted	Weighted
						Outstanding		Average	Average
								Exercise	Remaining
								Price	Contractual Life
	$0.55			$1.00		218,000		$0.76	5.08
	$1.01			$1.50		2,218,666		$1.09	8.17
	$1.51			$1.95		170,000		$1.68	7.54
	Total					2,606,666		$1.10	7.87
Schedule of Exercisable Options by Exercise Price Range [Table Text Block]	'
	Range of Exercise Prices
					Stock			Weighted
					Options			Average
					Exercisable			Exercise Price
	$0.55		$1.00		214,000			0.75
	$1.01		$1.50		992,831			1.14
	$1.51		$1.95		150,000			1.67
	Total				1,356,831			1.14
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	'
			Number of				Weighted Average
			Restricted Stock				Exercise Price
	Non-vested balance at January 1, 2013			29,334			$	1
	Changes during the period:
	Shares granted			-				-
	Shares vested			-				-
	Shares forfeited			-				-
	Non-vested balance at September 30, 2013			29,334			$	1

Note_9_Stock_Warrants_Tables

Note 9 - Stock Warrants (Tables)	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
			2013					2012
		Warrants			Weighted		Warrants		Weighted
					Average				Average
					Exercise Price				Exercise Price
	Beginning balance		782,259		$	0.85		1,235,877	$	0.35
	Stock warrants granted		-			-		-		-
	Stock warrants expired		-			-		-		-
	Stock warrants exercised		(427,713	)		0.55		-		-
	Ending balance		354,546		$	1.21		1,235,877	$	0.35

Note_1_Organization_Details

Note 1 - Organization (Details)	Sep. 30, 2013
	sqft
Disclosure Text Block [Abstract]	'
Area of Real Estate Property	25,000

Note_2_Liquidity_Details

Note 2 - Liquidity (Details) (USD $)

0 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

Aug. 02, 2013

Feb. 05, 2013

Feb. 28, 2013

Aug. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2010

Dec. 31, 2009

Jun. 30, 2013

Dec. 31, 2011

Policy Text Block [Abstract]

'

'

'

'

'

'

'

'

'

'

'

Cash and Cash Equivalents, at Carrying Value

'

'

'

'

$1,402,000

$1,775,000

$2,536,000

[1]

'

'

'

$2,914,000

Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

'

'

'

'

-755,000

-2,745,000

'

'

'

'

'

Working Capital

'

'

'

'

'

'

'

'

'

4,225,000

'

Proceeds from Issuance of Private Placement

'

'

'

'

'

'

2,000,000

7,213,000

5,304,000

'

'

Line of Credit Facility, Maximum Borrowing Capacity (in Dollars)

'

'

'

3,000,000

3,000,000

'

'

'

'

'

'

Proceeds from Lines of Credit (in Dollars)

1,000,000

1,000,000

1,000,000

1,000,000

'

'

'

'

'

'

'

Line of Credit Facility, Amount Outstanding

'

'

'

'

$3,000,000

'

'

'

'

'

'

[1]

Derived from the audited December 31, 2012 financial statements

Note_3_Summary_of_Significant_2

Note 3 - Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Note 3 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)	'	'	5,602,089	5,913,604
Accounts Payable and Accrued Liabilities	$0.30	$0	$0.30	$0
WholeSale Fees	0.1	0	0.4	0
Royalty Expense	0.5	0	1.5	0
Concentration Risk, Percentage	'	'	10.00%	'
Number of Customers	3	4	4	3
Percent of Revenue	49.00%	80.00%	55.00%	65.00%
Percentage of Accounts Receivable	54.00%	'	54.00%	'
Net of SRA Balance (Member)	'	'	'	'
Note 3 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Accounts Receivable, Net	0.5	0	0.5	0
Related to Royalties (Member)	'	'	'	'
Note 3 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Accounts Payable and Accrued Liabilities	$0.50	$0	$0.50	$0
Minimum [Member]	'	'	'	'
Note 3 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
WholeSaler, Percent of Chargebacks	90.00%	'	90.00%	'

Note_3_Summary_of_Significant_3

Note 3 - Summary of Significant Accounting Policies (Details) - Net revenues and accounts receivable balances iThe Company’s consolidated financial statements are presented net of SRA estimates (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'	'
Gross IGI product sales:	$3,038	'	$7,417	'
Reduction to gross product sales:	'	'	'	'
Chargebacks and billbacks	-1,395	'	-2,618	'
Sales discounts and other allowances	-254	'	-619	'
Total reduction to gross product sales	-1,649	'	-3,237	'
Net IGI product sales	3,950	1,464	11,124	4,835
Gross to Net Adjustments (Member)	'	'	'	'
Reduction to gross product sales:	'	'	'	'
Net IGI product sales	$1,389	'	$4,180	'

Note_4_Inventories_Details_Inv

Note 4 - Inventories (Details) - Inventories (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventories [Abstract]	'	'
Raw materials	$2,081	$1,673
Work in progress	162	26
Finished goods	280	74
Total	$2,523	$1,773	[1]
[1]	Derived from the audited December 31, 2012 financial statements

Note_5_StockBased_Compensation2

Note 5 - Stock-Based Compensation (Details) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

132 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

177 Months Ended

9 Months Ended

177 Months Ended

Apr. 12, 2010

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2009

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2009

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2009

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

19-May-10

19-May-10

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

1998 Directors Stock Plan [Member]

1999 Directors Stock Plan [Member]

1999 Directors Stock Plan [Member]

1999 Directors Stock Plan [Member]

1999 Stock Incentive Plan [Member]

1999 Stock Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

Minimum [Member]

Maximum [Member]

Maximum Number of Shares Allowed Per Year [Member]

Note 5 - Stock-Based Compensation (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

'

'

'

'

'

'

'

'

'

600,000

'

'

1,975,000

3,200,000

3,200,000

'

4,000,000

1,000,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

'

'

205,500

'

'

'

'

'

'

'

'

2,179,798

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

'

'

79,664

'

'

230,420

'

'

'

'

'

727,782

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

'

'

'

'

'

'

'

'

'

'

'one year

'

'

'

'

'

'

'

Award Term

'

'

'

'

'

'

'

'

'

'

'10 years

'10 years

'

'10 years

'10 years

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,892,500

'

'

'

Percent FMV Common Stock Options Granted

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'

'

'

'

'1 year

'3 years

'

'

'

'

'4 years

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

'

'

2,606,666

'

2,606,500

1,148,748

'

'

'

'

'

'

'

'

'

1,882,666

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)

'

'

$0.33

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value (in Dollars)

'

'

$1,873,180

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value (in Dollars)

'

'

929,055

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value (in Dollars)

'

'

92,976

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)

'

'

312,000

'

'

'

6,500

'

'

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense (in Dollars)

'

$104,200

'

'

'

'

$4,900

'

'

'

'

'

'

'

'

'

'

'

Note_5_StockBased_Compensation3

Note 5 - Stock-Based Compensation (Details) - Fair Value Assumptions of Option Awards	9 Months Ended
	Sep. 30, 2013
Note 5 - Stock-Based Compensation (Details) - Fair Value Assumptions of Option Awards [Line Items]	'
Risk-free rate	0.49%
Expected dividends	0.00%
Minimum [Member]	'
Note 5 - Stock-Based Compensation (Details) - Fair Value Assumptions of Option Awards [Line Items]	'
Expected volatility	36.90%
Expected term (in years)	'3 years 73 days
Maximum [Member]	'
Note 5 - Stock-Based Compensation (Details) - Fair Value Assumptions of Option Awards [Line Items]	'
Expected volatility	40.40%
Expected term (in years)	'3 years 109 days

Note_5_StockBased_Compensation4

Note 5 - Stock-Based Compensation (Details) - Option Activity (USD $)	9 Months Ended
	Sep. 30, 2013
Option Activity [Abstract]	'
Outstanding as of January 1, 2013	2,606,500
Outstanding as of January 1, 2013 (in Dollars per share)	$1.10
Issued	205,500
Issued (in Dollars per share)	$1.20
Exercised	-125,670
Exercised (in Dollars per share)	$1.08
Forfeited	-79,664
Forfeited (in Dollars per share)	$1.31
Outstanding as of September 30, 2013	2,606,666
Outstanding as of September 30, 2013 (in Dollars per share)	$1.10
Exercisable as of September 30, 2013	1,356,831
Exercisable as of September 30, 2013 (in Dollars per share)	$1.14

Note_5_StockBased_Compensation5

Note 5 - Stock-Based Compensation (Details) - Options Outstanding and Exercisable (USD $)	9 Months Ended
	Sep. 30, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Stock Options Outstanding (in Shares)	2,606,666
Weighted Average Exercise Price	$1.10
Weighted Average Remaining Contractual Life	'7 years 317 days
Range $.55 - $1.00 (Member)	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Stock Options Outstanding (in Shares)	218,000
Weighted Average Exercise Price	$0.76
Weighted Average Remaining Contractual Life	'5 years 29 days
Range $.55 - $1.00 (Member) | Minimum [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of Exercise Prices - Lower Limit	$0.55
Range $.55 - $1.00 (Member) | Maximum [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of Exercise Prices - Upper Limit	$1
Range $1.01 - $1.50 (Member)	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Stock Options Outstanding (in Shares)	2,218,666
Weighted Average Exercise Price	$1.09
Weighted Average Remaining Contractual Life	'8 years 62 days
Range $1.01 - $1.50 (Member) | Minimum [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of Exercise Prices - Lower Limit	$1.01
Range $1.01 - $1.50 (Member) | Maximum [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of Exercise Prices - Upper Limit	$1.50
Range $1.51 - $1.95 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Stock Options Outstanding (in Shares)	170,000
Weighted Average Exercise Price	$1.68
Weighted Average Remaining Contractual Life	'7 years 197 days
Range $1.51 - $1.95 [Member] | Minimum [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of Exercise Prices - Lower Limit	$1.51
Range $1.51 - $1.95 [Member] | Maximum [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of Exercise Prices - Upper Limit	$1.95

Note_5_StockBased_Compensation6

Note 5 - Stock-Based Compensation (Details) - Exercisable Options by Exercise Price (USD $)	9 Months Ended
	Sep. 30, 2013
Note 5 - Stock-Based Compensation (Details) - Exercisable Options by Exercise Price [Line Items]	'
Stock Options Exercisable (in Shares)	1,356,831
Exercisable - Weighted Average Exercise Price	$1.14
Exercisable [Member] | Range $.55 - $1.00 (Member)	'
Note 5 - Stock-Based Compensation (Details) - Exercisable Options by Exercise Price [Line Items]	'
Range of Exercise Prices - Lower Limit	$0.55
Range of Exercise Prices - Upper Limit	$1
Exercisable [Member] | Range $1.01 - $1.50 (Member)	'
Note 5 - Stock-Based Compensation (Details) - Exercisable Options by Exercise Price [Line Items]	'
Range of Exercise Prices - Lower Limit	$1.01
Range of Exercise Prices - Upper Limit	$1.50
Exercisable [Member] | Range $1.51 - $1.95 [Member]	'
Note 5 - Stock-Based Compensation (Details) - Exercisable Options by Exercise Price [Line Items]	'
Range of Exercise Prices - Lower Limit	$1.51
Range of Exercise Prices - Upper Limit	$1.95
Range $.55 - $1.00 (Member)	'
Note 5 - Stock-Based Compensation (Details) - Exercisable Options by Exercise Price [Line Items]	'
Stock Options Exercisable (in Shares)	214,000
Exercisable - Weighted Average Exercise Price	$0.75
Range $1.01 - $1.50 (Member)	'
Note 5 - Stock-Based Compensation (Details) - Exercisable Options by Exercise Price [Line Items]	'
Stock Options Exercisable (in Shares)	992,831
Exercisable - Weighted Average Exercise Price	$1.14
Range $1.51 - $1.95 [Member]	'
Note 5 - Stock-Based Compensation (Details) - Exercisable Options by Exercise Price [Line Items]	'
Stock Options Exercisable (in Shares)	150,000
Exercisable - Weighted Average Exercise Price	$1.67

Note_5_StockBased_Compensation7

Note 5 - Stock-Based Compensation (Details) - Restricted Stock Awards (USD $)	Sep. 30, 2013	Dec. 31, 2012
Restricted Stock Awards [Abstract]	'	'
Non-vested balance at January 1, 2013	29,334	29,334
Non-vested balance at January 1, 2013 (in Dollars per share)	$1	$1
Non-vested balance at September 30, 2013	29,334	29,334
Non-vested balance at September 30, 2013 (in Dollars per share)	$1	$1

Note_6_Income_Taxes_Details

Note 6 - Income Taxes (Details)	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Equity Method Investment, Ownership Percentage	50.00%
Stockholder Ownership, Percent	5.00%

Note_7_License_Fee_Details

Note 7 - License Fee (Details) (USD $)	Dec. 12, 2005	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
		Licensing Agreements [Member]	Licensing Agreements [Member]	Licensing Agreements [Member]	Licensing Agreements [Member]
Note 7 - License Fee (Details) [Line Items]	'	'	'	'	'
Number of Years	'10 years	'	'	'	'
Finite-Lived License Agreements, Gross	$1,000,000	'	'	'	'
Amortization	'	$25,000	$25,000	$75,000	$75,000

Note_8_Note_Payable_Bank_Detai

Note 8 - Note Payable - Bank (Details) (USD $)

0 Months Ended

1 Months Ended

1 Months Ended

9 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

Aug. 02, 2013

Feb. 05, 2013

Feb. 28, 2013

Aug. 31, 2012

Sep. 30, 2013

Jul. 26, 2013

Sep. 30, 2013

Jul. 26, 2013

Jul. 26, 2013

Sep. 30, 2013

Jul. 26, 2013

Sep. 30, 2013

Jul. 26, 2013

Sep. 30, 2013

Dec. 31, 2012

Jul. 26, 2013

Sep. 30, 2013

Jul. 26, 2013

Sep. 30, 2013

Jul. 26, 2013

Sep. 30, 2013

Above Prime Rate [Member]

Above Prime Rate [Member]

Comany Remains in Compliance through December 2013 [Member]

Comany Remains in Compliance through December 2013 [Member]

Formula Revolving Line (Member)

Formula Revolving Line (Member)

Formula Revolving Line (Member)

Non-Formula Revolving Line (Member)

Non-Formula Revolving Line (Member)

Non-Formula Revolving Line (Member)

Non-Formula Revolving Line (Member)

Non-Formula Revolving Line (Member)

Maximum [Member]

Maximum [Member]

Minimum [Member]

Minimum [Member]

Formula Revolving Line (Member)

Formula Revolving Line (Member)

Original Aggregate Borrowing Amount [Member]

Above Prime Rate [Member]

Maximum [Member]

Maximum [Member]

Note 8 - Note Payable - Bank (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Lines of Credit (in Dollars)

$1,000,000

$1,000,000

$1,000,000

$1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Maximum Borrowing Capacity (in Dollars)

'

'

'

$3,000,000

$3,000,000

'

'

$3,000,000

$5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Basis Spread on Variable Rate

'

'

'

'

'

4.90%

1.90%

'

'

2.40%

5.15%

2.15%

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Interest Rate During Period

'

'

'

'

'

'

'

'

'

'

'

'

8.65%

5.65%

6.15%

8.90%

5.90%

'

'

'

'

Liquidity Ratio

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

1.25

0.9

1

Note_9_Stock_Warrants_Details

Note 9 - Stock Warrants (Details) (USD $)	Sep. 30, 2013	Feb. 08, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011	Dec. 08, 2010	Dec. 12, 2005
Note 9 - Stock Warrants (Details) [Line Items]	'	'	'	'	'	'	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	354,546	427,713	782,259	1,235,877	1,235,877	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)	1.21	0.55	0.85	0.35	0.35	1.21	'
Number of Years	'	'	'	'	'	'	'10 years
Warrants Issued, Fair Value Disclosure (in Dollars)	'	$209,000	'	'	'	'	'
Warrants Issued in Connection with Private Placement Offering [Member]	'	'	'	'	'	'	'
Note 9 - Stock Warrants (Details) [Line Items]	'	'	'	'	'	'	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	'	'	387,201	'	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)	'	'	0.01	'	'	'	'
Number of Years	'	'10 years	'	'	'	'	'
First Placement Agent [Member]	'	'	'	'	'	'	'
Note 9 - Stock Warrants (Details) [Line Items]	'	'	'	'	'	'	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	'	'	'	'	'	338,182	'
Second Placement Agent [Member]	'	'	'	'	'	'	'
Note 9 - Stock Warrants (Details) [Line Items]	'	'	'	'	'	'	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	'	'	'	'	'	16,364	'

Note_9_Stock_Warrants_Details_

Note 9 - Stock Warrants (Details) - Stock Warrants Activity (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Feb. 08, 2013	Dec. 08, 2010
Stock Warrants Activity [Abstract]	'	'	'	'
Beginning balance	782,259	1,235,877	427,713	'
Beginning balance (in Dollars per Item)	0.85	0.35	0.55	1.21
Stock warrants granted	0	0	'	'
Stock warrants granted (in Dollars per share)	$0	$0	'	'
Stock warrants expired	0	0	'	'
Stock warrants expired (in Dollars per share)	$0	$0	'	'
Stock warrants exercised	-427,713	'	'	'
Stock warrants exercised (in Dollars per share)	$0.55	'	'	'
Ending balance	354,546	1,235,877	427,713	'
Ending balance (in Dollars per Item)	1.21	0.35	0.55	1.21

Note_10_Asset_Purchase_Agreeme1

Note 10 - Asset Purchase Agreement (Details) (USD $)	0 Months Ended
	Feb. 02, 2013
Asset Purchase Agreement Disclosure [Abstract]	'
Payments to Acquire Other Productive Assets	$1,400,000
Milestone Payment	$400,000
Finite-Lived Intangible Asset, Useful Life	'15 years
No Compete Contract, Number of Years	'seven